The M&A Class Action Firm Continues Investigating The Merger...| MENAFN.COM

Sunday, 25 September 2022 11:45 GMT

The M&A Class Action Firm Continues Investigating The Merger VIVO, AERI, CYBE, GMTX


(MENAFN- GlobeNewsWire - Nasdaq)

NEW YORK, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the“M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:

  • Meridian Bioscience, Inc. ( VIVO ) relating to its proposed acquisition by SD Biosensor, Inc. and SJL Partners LLC. Under the terms of the agreement, VIVO shareholders will receive $34.00 in cash per share they own. Click here for more information: . It is free and there is no cost or obligation to you.
  • Aerie Pharmaceuticals, Inc. ( AERI ) , relating to its proposed acquisition by Alcon Inc. Under the terms of the agreement, AERI shareholders are expected to receive $15.25 in cash per share they own. Click here for more information: . It is free and there is no cost or obligation to you.
  • CyberOptics Corp. ( CYBE ) , relating to its proposed acquisition by Nordson Corp. Under the terms of the agreement, CYBE shareholders are expected to receive $54.00 in cash per share they own. Click here for more information: . It is free and there is no cost or obligation to you.
  • Gemini Therapeutics, Inc. ( GMTX ) , relating to its proposed merger with Disc Medicine, Inc. Under the terms of the agreement, GMTX shareholders are expected to own 28% of the newly combined company. Click here for more information: . It is free and there is no cost or obligation to you.

About Monteverde & Associates PC

We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing. We were listed in the Top 50 in the 2018-2021 ISS Securities Class Action Services Report. Our lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions. Mr. Monteverde is recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an award given to less than 2.5% of attorneys in a particular field. He has also been selected by Martindale-Hubbell as a 2017-2021 Top Rated Lawyer. Our firm's recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019). Also, in 2019 we recovered or secured six cash common funds for shareholders in mergers & acquisitions class action cases.

If you own common stock in any of the above listed companies and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at or by telephone at (212) 971-1341.

Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America

Tel: (212) 971-1341

Attorney Advertising. (C) 2022 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC ( ). Prior results do not guarantee a similar outcome with respect to any future matter.




Tags VIVO AERI CYBE GMTX Meridian Bioscience Aerie Pharmaceuticals CyberOptics Gemini Therapeutics Class Action

MENAFN22092022004107003653ID1104909592


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.